UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Annals of oncology, 2018-12, Vol.29 (12), p.2341-2347

2018

Volltextzugriff (PDF)

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Volltextzugriff (PDF)

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Annals of oncology, 2022-04, Vol.33 (4), p.384-394

2022

Volltextzugriff (PDF)

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Annals of oncology, 2022-11, Vol.33 (11), p.1149-1158

2022

Volltextzugriff (PDF)

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

ESMO open, 2022-08, Vol.7 (4), p.100553, Article 100553

2022

Volltextzugriff (PDF)

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Annals of oncology, 2020-09, Vol.31 (9), p.1216-1222

2020

Volltextzugriff (PDF)

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Annals of oncology, 2021-01, Vol.32 (1), p.49-57

2021

Volltextzugriff (PDF)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of oncology, 2016-08, Vol.27 (8), p.1519-1525

2016

Volltextzugriff (PDF)

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

European journal of cancer (1990), 2013-05, Vol.49 (8), p.1825-1835

2013

Volltextzugriff (PDF)

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Annals of oncology, 2021-08, Vol.32 (8), p.1005-1014

2021

Volltextzugriff (PDF)

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Annals of oncology, 2007-12, Vol.18 (12), p.1927-1934

2007

Volltextzugriff (PDF)

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Annals of oncology, 2015-01, Vol.26 (1), p.95-100

2015

Volltextzugriff (PDF)

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

Annals of oncology, 2016-03, Vol.27 (3), p.379-390

2016

Volltextzugriff (PDF)

Better Angels II

The Massachusetts review, 2019-07, Vol.60 (2), p.337-338

Untch, M. A

2019

Volltextzugriff (PDF)

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Annals of oncology, 2017-03, Vol.28 (3), p.497-504

2017

Volltextzugriff (PDF)

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

Annals of oncology, 2024-05, Vol.35 (5), p.429-436

2024

Volltextzugriff (PDF)

Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer

JNCI : Journal of the National Cancer Institute, 2003-01, Vol.95 (2), p.142-153

2003

Volltextzugriff (PDF)

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Annals of oncology, 2013-12, Vol.24 (12), p.2978-2984

2013

Volltextzugriff (PDF)

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Annals of oncology, 2014-01, Vol.25 (1), p.81-89

2014

Volltextzugriff (PDF)

Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer—a problem still to be solved

Annals of oncology, 2014-03, Vol.25 (3), p.754-754

2014

Volltextzugriff (PDF)

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study

Annals of oncology, 2016-11, Vol.27 (11), p.2053-2059

2016

Volltextzugriff (PDF)

Adjuvante und neoadjuvante Chemotherapie des Mammakarzinoms

Der Onkologe, 2015-03, Vol.21 (3), p.231-238

2015

Volltextzugriff (PDF)

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

Annals of oncology, 2019-01, Vol.30 (1), p.109-114

2019

Volltextzugriff (PDF)

1 – 25 von 854

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(743)
Mit Volltextzugriff
(701)

Publikationsform

Sprache

Englisch
(678)
Deutsch
(188)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(252)
Humans
(251)
Life Sciences & Biomedicine
(240)
Female
(224)
Oncology
(185)
Breast Cancer
(124)
Middle Aged
(114)
Adult
(103)
Breast Neoplasms - Drug Therapy
(102)
Breast Neoplasms - Pathology
(86)
Biological And Medical Sciences
(84)
Medical Sciences
(84)
Aged
(82)
Tumors
(80)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(62)
Chemotherapy
(61)
Medicin Och Hälsovetenskap
(50)
Treatment Outcome
(50)
Chemotherapy, Adjuvant
(48)
Gynecology. Andrology. Obstetrics
(41)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(122)
Cancer Research
(110)
Journal Of Clinical Oncology
(59)
Geburtshilfe Und Frauenheilkunde
(33)
European Journal Of Cancer
(30)
Gynäkologisch-Geburtshilfliche Rundschau
(30)
Gynäkologe
(25)
Senologie
(16)
Gynäkologie
(15)
Radiologe
(15)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

Better Angels II

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer—a problem still to be solved

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2− early breast cancer: final invasive disease–free survival results from the NATALEE trial

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study

Adjuvante und neoadjuvante Chemotherapie des Mammakarzinoms

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288]

Suchergebnisse filtern